Loading
NewLink Genetics (now Lumos Pharma)
The Iowa biotech that ran the largest pancreatic cancer vaccine trial, IMPRESS, and the IDO inhibitor indoximod programme; it merged into Lumos Pharma in 2020.
Also called: Lumos Pharma
Overview
NewLink Genetics developed the HyperAcute whole-cell vaccine platform, including algenpantucel-L for pancreatic cancer, and the IDO pathway inhibitor indoximod. After IMPRESS and PILLAR failed, the company merged with Lumos Pharma in 2020 and left oncology.
Headquarters
Ames, Iowa, United States, US
Scorecard
All companies#491of 1245 companies, score 4
- modalities +2
- registry trials +5
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1999
Products
1NegativeAllogeneic whole-cell vaccine expressing alpha-gal
Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit.
Connected
3Similar pages
cancers
drugs
NegativeAllogeneic whole-cell vaccine expressing alpha-gal
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
Wikipedia · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Apply the update bot's proposals (PR 16) · diff · file
Sourced, not expert-reviewed